Dima Raskolnikov1, Soroush Rais-Bahrami1, Arvin K George1, Baris Turkbey2, Nabeel A Shakir1, Chinonyerem Okoro1, Jason T Rothwax1, Annerleim Walton-Diaz1, M Minhaj Siddiqui1, Daniel Su1, Lambros Stamatakis1, Pingkun Yan3, Jochen Kruecker3, Sheng Xu4, Maria J Merino5, Peter L Choyke2, Bradford J Wood6, Peter A Pinto7. 1. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 2. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3. Philips Research North America, Briarcliff Manor, New York. 4. Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Clinical Center, National Institutes of Health, Bethesda, Maryland. 5. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 6. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Clinical Center, National Institutes of Health, Bethesda, Maryland. 7. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Clinical Center, National Institutes of Health, Bethesda, Maryland. Electronic address: pintop@mail.nih.gov.
Abstract
PURPOSE: Men diagnosed with atypical small acinar proliferation are counseled to undergo early rebiopsy because the risk of prostate cancer is high. However, random rebiopsies may not resample areas of concern. Magnetic resonance imaging/transrectal ultrasound fusion guided biopsy offers an opportunity to accurately target and later retarget specific areas in the prostate. We describe the ability of magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy to detect prostate cancer in areas with an initial diagnosis of atypical small acinar proliferation. MATERIALS AND METHODS: Multiparametric magnetic resonance imaging of the prostate and magnetic resonance imaging/transrectal ultrasound fusion guided biopsy were performed in 1,028 patients from March 2007 to February 2014. Of the men 20 met the stringent study inclusion criteria, which were no prostate cancer history, index biopsy showing at least 1 core of atypical small acinar proliferation with benign glands in all remaining cores and fusion targeted rebiopsy with at least 1 targeted core directly resampling an area of the prostate that previously contained atypical small acinar proliferation. RESULTS: At index biopsy median age of the 20 patients was 60 years (IQR 57-64) and median prostate specific antigen was 5.92 ng/ml (IQR 3.34-7.48). At fusion targeted rebiopsy at a median of 11.6 months 5 of 20 patients (25%, 95% CI 6.02-43.98) were diagnosed with primary Gleason grade 3, low volume prostate cancer. On fusion rebiopsy cores that directly retargeted areas of previous atypical small acinar proliferation detected the highest tumor burden. CONCLUSIONS: When magnetic resonance imaging/transrectal ultrasound fusion guided biopsy detects isolated atypical small acinar proliferation on index biopsy, early rebiopsy is unlikely to detect clinically significant prostate cancer. Cores that retarget areas of previous atypical small acinar proliferation are more effective than random rebiopsy cores.
PURPOSE:Men diagnosed with atypical small acinar proliferation are counseled to undergo early rebiopsy because the risk of prostate cancer is high. However, random rebiopsies may not resample areas of concern. Magnetic resonance imaging/transrectal ultrasound fusion guided biopsy offers an opportunity to accurately target and later retarget specific areas in the prostate. We describe the ability of magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy to detect prostate cancer in areas with an initial diagnosis of atypical small acinar proliferation. MATERIALS AND METHODS: Multiparametric magnetic resonance imaging of the prostate and magnetic resonance imaging/transrectal ultrasound fusion guided biopsy were performed in 1,028 patients from March 2007 to February 2014. Of the men 20 met the stringent study inclusion criteria, which were no prostate cancer history, index biopsy showing at least 1 core of atypical small acinar proliferation with benign glands in all remaining cores and fusion targeted rebiopsy with at least 1 targeted core directly resampling an area of the prostate that previously contained atypical small acinar proliferation. RESULTS: At index biopsy median age of the 20 patients was 60 years (IQR 57-64) and median prostate specific antigen was 5.92 ng/ml (IQR 3.34-7.48). At fusion targeted rebiopsy at a median of 11.6 months 5 of 20 patients (25%, 95% CI 6.02-43.98) were diagnosed with primary Gleason grade 3, low volume prostate cancer. On fusion rebiopsy cores that directly retargeted areas of previous atypical small acinar proliferation detected the highest tumor burden. CONCLUSIONS: When magnetic resonance imaging/transrectal ultrasound fusion guided biopsy detects isolated atypical small acinar proliferation on index biopsy, early rebiopsy is unlikely to detect clinically significant prostate cancer. Cores that retarget areas of previous atypical small acinar proliferation are more effective than random rebiopsy cores.
Authors: Lambros Stamatakis; M Minhaj Siddiqui; Jeffrey W Nix; Jennifer Logan; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Anthony N Hoang; Srinivas Vourganti; Hong Truong; Brian Shuch; Howard L Parnes; Baris Turkbey; Peter L Choyke; Bradford J Wood; Richard M Simon; Peter A Pinto Journal: Cancer Date: 2013-07-02 Impact factor: 6.860
Authors: Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood Journal: J Urol Date: 2011-08-17 Impact factor: 7.450
Authors: Baris Turkbey; Peter A Pinto; Haresh Mani; Marcelino Bernardo; Yuxi Pang; Yolanda L McKinney; Kiranpreet Khurana; Gregory C Ravizzini; Paul S Albert; Maria J Merino; Peter L Choyke Journal: Radiology Date: 2010-04 Impact factor: 11.105
Authors: Jennifer L Merrimen; Glenn Jones; Sundus A B Hussein; Chung S Leung; Linda R Kapusta; John R Srigley Journal: J Urol Date: 2011-02-22 Impact factor: 7.450
Authors: Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto Journal: Diagn Interv Radiol Date: 2014 Jul-Aug Impact factor: 2.630
Authors: Soroush Rais-Bahrami; M Minhaj Siddiqui; Baris Turkbey; Lambros Stamatakis; Jennifer Logan; Anthony N Hoang; Annerleim Walton-Diaz; Srinivas Vourganti; Hong Truong; Jochen Kruecker; Maria J Merino; Bradford J Wood; Peter L Choyke; Peter A Pinto Journal: J Urol Date: 2013-05-29 Impact factor: 7.450
Authors: Dima Raskolnikov; Soroush Rais-Bahrami; Baris Turkbey; Ardeshir R Rastinehad; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: Urol Pract Date: 2014-03-04
Authors: M Minhaj Siddiqui; Soroush Rais-Bahrami; Hong Truong; Lambros Stamatakis; Srinivas Vourganti; Jeffrey Nix; Anthony N Hoang; Annerleim Walton-Diaz; Brian Shuch; Michael Weintraub; Jochen Kruecker; Hayet Amalou; Baris Turkbey; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: Eur Urol Date: 2013-06-12 Impact factor: 20.096
Authors: Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto Journal: Future Oncol Date: 2016-07-12 Impact factor: 3.404
Authors: Akhil Muthigi; Arvin K George; Abhinav Sidana; Michael Kongnyuy; Richard Simon; Vanessa Moreno; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2016-08-28 Impact factor: 7.450
Authors: Dima Raskolnikov; Arvin K George; Soroush Rais-Bahrami; Baris Turkbey; M Minhaj Siddiqui; Nabeel A Shakir; Chinonyerem Okoro; Jason T Rothwax; Annerleim Walton-Diaz; Sandeep Sankineni; Daniel Su; Lambros Stamatakis; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2015-01-23 Impact factor: 7.450
Authors: Jeffrey J Tosoian; Ridwan Alam; Mark W Ball; H Ballentine Carter; Jonathan I Epstein Journal: Nat Rev Urol Date: 2017-08-31 Impact factor: 14.432
Authors: Chinonyerem Okoro; Arvin K George; M Minhaj Siddiqui; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Nabeel A Shakir; Jason T Rothwax; Dima Raskolnikov; Lambros Stamatakis; Daniel Su; Baris Turkbey; Peter L Choyke; Maria J Merino; Howard L Parnes; Bradford J Wood; Peter A Pinto Journal: J Endourol Date: 2015-07-23 Impact factor: 2.942
Authors: Gregory S Merrick; Robert W Galbreath; Abbey Bennett; Wayne M Butler; Edward Amamovich Journal: World J Urol Date: 2016-11-29 Impact factor: 4.226
Authors: Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto Journal: Abdom Radiol (NY) Date: 2016-05